results taken from a healthy population (Diamandis, Fritsche, Lija, Chan, & Schwartz, 2002) and is therefore raised in 1%-2% of healthy individuals, dependent on the relative bias of the CA125 method.
CA125 is also raised in 5% of benign gynaecological conditions and in 28% of non-gynaecological cancers (Coyler, 2012) . There is currently no other biomarker or biomarker panel that has shown greater accuracy than CA125 for Ovarian cancer in primary care although other biomarkers such as human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) index continue to be evaluated (Soletormos et al., 2016; Sundar et al., 2015; Wei, Li, & Zhang, 2016; Zhu et al., 2011) .
To reduce the impact of false-positive CA125 measurements, NICE recommended that in UK primary care: (a) only women with persistent or frequent symptoms (particularly over 12 times a month) should first be offered a CA125 test; (b) CA125 should be used "especially" in women over 50 years (the postmenopausal); (c) a single raised value >35 IU/L should first trigger an ultrasound scan (USS) of the abdomen and pelvis and only if both tests are abnormal then an urgent referral is indicated (although NICE provided no guidance on what constitutes an abnormal USS) (NICE, 2015) . Following referral to secondary care, the Royal College of Obstetrics and Gynaecology (RCOG) recommends that the Risk of Malignancy Index (RMI) score is used to determine ongoing management, combining CA125, menopausal status, and USS findings (RCOG, 2016; RCOG & BSGE, 2011) . There is no established pathway for the management of cases referred with a raised CA125 alone.
The aim of this study was to describe patterns of CA125 testing in Oxfordshire, UK, by age-group over an 11-year period from 2003 to 2014 to include the release of the NICE guidance in terms of: (a) trends in CA125 use, (b) the proportion of positive tests in primary care and (c) the frequency of testing in primary care patients with multiple CA125 samples.
| ME THODS

| Study setting
The Oxford University Hospitals Trust (OUHT) Clinical Biochemistry laboratory serves the county of Oxfordshire with a population of approximately 660,000. As consultant head of biochemistry, one of the researchers (BS) had full access to the data held on the laboratory information system which holds all results produced since the mid-1980s. For analysis, all data were fully anonymised. We estimated the number of women residing in the catchment area for the laboratory by deriving weights from population pyramid data for mid-2012 and multiplying these by the total population size. We assumed that the population was 660,000 in 2012 and increased at a rate of 0.96% per year since 2002 based on regional population data (Oxford City Council, 2013) . All CA125 analyses were undertaken using a single method, the Siemens Centaur XP analyser (Siemens Healthcare, Frimley, UK) by chemiluminescence immunoassay.
Method reproducibility expressed as % coefficient of variation was 5.3% at 28.9 IU/L, 6.3% at 69.7 IU/L, 6.3% at 188.0 IU/L.
| Study sample
We searched the laboratory database for all CA125 tests from 2002 to 2014, recording the sex and date of birth of the patient, specimen date, requesting doctor, requestor location and CA125 value. Samples from males were excluded. Requestor location was categorised into primary care, secondary care, research, out of Oxfordshire, hospice, unknown. Only primary care and secondary care samples were included in the analysis. The NICE guidance CG 122 (NICE, 2011) uses age 50 years to guide patient investigation, and therefore, age was divided into four categories, using cut points of 25, 50 and 75 years in order to obtain broad age quartiles.
Because the UK NICE ovarian cancer guidelines were released on April 27th 2011, we organised data into three-month periods starting in May, August, November and February (NICE, 2011) . In order to have data for complete years, we examined data from May 2003 to April 2014.
| Statistical analysis
| Testing over time
We calculated the number of women having their first CA125 test from either primary or secondary care by age category per threemonth interval and the rates of new tests (per 10,000 women) by dividing the total number of tests by the estimated population. We calculated the total number of CA125 samples in each year over the study period. We used negative binomial regression to assess the effect of the introduction of the national guideline on CA125 testing controlling for age-specific trends in testing. The model was specified such that we could test both the immediate effect of the guideline on testing, the effect on the trend over time, and interaction of the trend for each age quartile.
| Positive tests over time
Using a cut-off value of 35 IU/L, we examined the proportions and rates of positive CA125 results (>35 UI/L) in women undergoing their first CA125 test and assessed the impact of the guideline. We stratified tests into yearly intervals from May 1st to April 30th because of the low number of positive tests in women less than 50 years of age.
We used logistic regression to test the effect of the guideline release on the probability of the first CA125 value being positive controlling for age and trend over time.
| Retesting and serial testing
We also looked at the number of tests performed in primary care in the 2 years following the first CA125 test in each patient and how this changed over time. As we did not have access to clinical information about the reason for testing, we assumed that all tests requested from primary care were for diagnosis and not for monitoring treatment, as the vast majority of monitoring following diagnosis is led by hospital specialists in Oxfordshire. We classified women either having one or two CA125 tests in a 2-year period, or having three or more tests in a 2-year period. In order for each test to have a full two years following the first test, we included only tests that were undertaken between May 1st 2003 and 30st April 2012 in this analysis. We tested the impact of the guidelines on intensity of CA125 testing following the release of the guideline using logistic regression models adjusted for age and year and the value of the first test result. We also examined the proportion and the odds of GPs second test (retesting) and of performing serial testing in primary care in relation to the first CA125 value. All analyses were performed using R version 3.3.0. 
| RE SULTS
| Testing over time
The largest change in CA125 testing was in primary care, where the number of patients being tested for the first time increased 10-fold from 528 to 5,082 (Figure 1a upper panel). The rates of CA125 tests per 10,000 women broadly reflected the trend for increasing numbers of women being tested. However, rates of CA125 tests in primary care increased sharply by 76% (95% C.I. 55% to 100%) in the three months following the introduction of the national guideline (Figure 1b upper panel) . The rates of testing increased at an average of 24% (95% C.I. 22% to 26%) per year before the guideline and reduced to 5% (95% C.I. 1% to 12%) per year thereafter (Figure 1b upper panel). In contrast, the testing remained relatively stable in secondary care, with no change in the absolute number of tests requested nor the rate of testing over time (Figure 1a ,b lower panels).
Most women tested in primary care were aged 25-50 or 50-75 years, but due to the smaller numbers of older women in the population, the greatest increase in rates were observed in the 50-75 and 75 + year age-groups (Figure 1 ). Despite this, the sharp increase following the introduction of the national guidelines does not differ significantly between age quartiles (Table A1) .
| Positive tests
Among all the primary care patients being tested for the first time, 5% of test results were positive (>35 IU/L), varying by age quartile: 3%, 5%, 5% and 10%,respectively. Rates of positive tests increased by an average of 11% (95% C.I. 8% to 14%) per year before the guideline was introduced, sharply increasing by 65% (95% C.I. 50%
to 81%) in the year following the guideline, then decreasing at an average of 6% (95% C.I. 1% to 11%) per year following this ( Figure 2a and Table A2) . (Figure 2b and Table A3 ).
| Repeat versus serial testing over time
84% of women tested in primary care had a single CA125 test on record, 12% had two tests and 4% had three or more CA125 tests.
These proportions changed over time from 80%, 13% and 7% aged ≥75 years (OR = 1.65, 95% C.I. 1.27 to 2.13) were more likely to be tested more than twice in 2 years rather than once or twice over 2 years compared to women aged 25-50 years. The introduction of the guideline had no effect on the probability that tests were used more than twice (OR = 0.81, 95% C.I. 0.62 to 1.06) rather than once or twice. The trend in the odds of tests being used more than twice decreased by 5% (95% C.I 2% to 8%) per year ( Figure 3a and Table   A4 ).
The value of the first test was associated with an increase in the odds of further testing being done (Figure 3b) . and Table A5 ). Retesting and serial testing in primary care were both associated with the initial CA125 value in all age-groups with no significant difference between women whose first test was 30-35 and >35 IU/L.
| D ISCUSS I ON
| Summary of findings
| Strengths and limitations
We present a consecutive sample of 51,033 CA125 tests analysed using the same method over a 10-year period, by the only laboratory serving the population of a well-defined region allowing comprehensive analysis of trends in CA125 use over time in relation to population-level cancer incidence data. While the population studied is typical of the wider UK population in terms of age, Oxfordshire has lower than average deprivation scores and so help seeking behaviour leading to CA125 testing in primary care may not be representative of more deprived regions of the UK. At the time of this analysis, we could not access data on the patient demographics to confirm or refute this nor could we access past medical history, the symptoms leading to primary care testing, nor other investigations performed before or after CA125 (imaging and histology). Consequently, we are unable to confirm whether CA125 results were true-or false-positive (or negative). Our findings without these data still have direct relevance to referral volume to secondary care where all positive CA125s must be investigated. We have also made the assumption that all CA125 requests were made to investigate ovarian cancer, although CA125 may have been requested against primary care guidance or following specialist advice as a marker for another malignancy, in particular before the introduction of the 2011 guideline.
To reduce the risk of this, we restricted the first two analyses of the first primary care CA125 sample in females.
| Interpretation
To our knowledge, this is the largest published analysis of primary care CA125 data to date. release (Ford, Marshall, & Crawford, 2013) . Our data support this finding but show that some of the increase was likely a continuation of an upward trend in primary care testing observed throughout the preceding decade. Despite most raised CA125 values being followed up in the hospital record, there was no change in the number of diagnoses made in Airedale, and the most common cause of an increased CA125 was benign pathology (Ford et al., 2013) . A more recent audit from two NHS hospitals showed that only 10% of urgent referrals for suspected ovarian cancer were preceded by a CA125 then USS test, that a third (37.78%) of patients referred were younger than 50 years old, and a similar proportion were referred without any initial primary care testing (Rai et al., 2015) : our analysis confirms that CA125 continues to be used in premenopausal women for whom false-positive results are much more likely due to benign conditions such as the follicular phase of the menstrual cycle, pregnancy, ovarian cysts and pelvic inflammatory disease.
The prospective Diagnosing Ovarian Cancer Early (DOvE) pilot study reported that in women over 50 years, a symptom-triggered strategy led to a reduction in tumour volume at diagnosis (without improvement in stage at diagnosis) allowing a higher rate of complete surgical resection (Gilbert et al., 2012) . In DOvE, all patients received CA125 testing at an initial assessment after referral for abdominal and non-specific symptoms lasting for >2 weeks, and an ultrasound was performed, regardless of the CA125 result, 2 weeks later (Gilbert et al., 2012) . DoVE (in symptomatic patients) and UKCTOCS (in a screened population) have found that a multi-modal strategy involving both CA125 and ultrasound is most effective at detecting ovarian cancer, as CA125 can detect low-volume disease before ultrasound can (Gilbert et al., 2012; Jacobs et al., 2016) .
We have identified no research demonstrating that any biomarker, such as HE4, or diagnostic strategy, for example repeat single CA125 measurements or CA125 trend, (Jacobs et al., 2016; Zhu et al., 2011 ) that has superior diagnostic accuracy. HE4 has undergone significant evaluation in secondary care, and meta-analysis indicates that it is more specific for ovarian cancer than CA125 (Bandiera et al., 2011; Escudero et al., 2011; Yu, Yang, Xie, & Bao, 2012) . However, most of these studies have been conducted in patients with a preidentified pelvic mass or preidentified cancer, with some studies including healthy controls. While HE4 has potential utility in primary care, it has never been evaluated in this setting (NICE, 2011; Sundar et al., 2015) .
Our finding that the likelihood of repeat and serial testing is no different between initial CA125 values of 30-35 IU/L and >35 IU/L is novel, and reflects the clinical reality that GPs will not be reassured by a CA125 result under but close to the threshold in a symptomatic patient.
Myers et al showed that CA125 testing has greater accuracy in postmenopausal women (sensitivity 69%-87%; specificity 81%-100%) where the prevalence of disease is higher than in premenopausal women (sensitivity 50%-74%; specificity 26%-95%) (Myers et al., 2006) . Using our data from 2013, we can estimate that there were five patients with positive CA125 results for every one patient with ovarian cancer in the <50 years age-group compared to two to one in those >50 years. NICE decided against using age as a threshold for testing so that the 20% of premenopausal ovarian cancer patients would not be disadvantaged. NICE recommended that CA125 testing is carried out in symptomatic women "(especially if 50 or over)"; however, an alternative strategy could be to recommend a higher CA125 threshold in the premenopausal given the many causes of false positives in this age-group (NICE, 2011) . At present, these data remain unreported in primary care populations.
| CON CLUS IONS
Collaborative primary and secondary care research is needed to develop more detailed pathways for the investigation and management of patients presenting with symptoms of ovarian cancer to further quantify the potential physical and economic costs of further investigation of symptomatic women investigated with CA125 in primary care. These data are available through electronic health records:
our team and others are working on data linkage to answer these questions. 
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